Here is what the page “Most Cancer Drugs Approved by European Regulators Lack High Clinical Benefit, Analysis Fin” contains. A new analysis reveals that most cancer medicines approved by the European Medicines Agency between 2017 and 2020 do not demonstrate a high clinical benefit. The study, published in The BMJ, assessed 131 cancer drugs approved during that period using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). It found that only about a quarter of the drugs met the threshold for a substantial improvement in survival or quality of life.
The findings raise concerns about the standards for drug approval in Europe, where regulators often rely on surrogate endpoints like tumor shrinkage rather than patient-centered outcomes. Courtney Davis from King's College London emphasized that patients and clinicians may overestimate the benefits of new cancer treatments. The full version stays on the original page, which this listing opens directly.